Albumin's Role in Fighting Mucormycosis
Author Information
Author(s): Chamilos Georgios, Pikoulas Antonis, Morianos Ioannis, Nidris Vassilis, Hamdy Rania, López-López Angeles, Moran-Garrido Maria, Muthu Valliappan, Halabalaki Maria, Papadovasilaki Maria, Irene Kyrmizi, Gu Yiyou, Aerts Robina, Mercier Toine, Vanbiervliet Yuri, Cho Sung-Yeon, Spallone Amy, Samonakis Dimitrios, Kastritis Efstathios, Drakos Elias, Tzardi Maria, Eliopoulos Aristides, Georgila Konstantina, Carvalho Agostinho, Kurzai Oliver, Rudramurthy Shivaprakash, Lanternier Fanny, Petratos Kyriacos, Maertens Johan, Bruno Vincent, Kontoyiannis Dimitrios, Barbas Coral, Soliman Sameh, Ibrahim Ashraf
Primary Institution: Institute of Molecular Biology and Biotechnology, FORTH, Hellas
Hypothesis
Uncharacterized host metabolic effectors confer protective immunity against mucormycosis.
Conclusion
Albumin plays a crucial role in inhibiting the growth of Mucorales and modulating their pathogenicity.
Supporting Evidence
- Severe hypoalbuminemia is a prominent metabolic abnormality in mucormycosis patients.
- Purified albumin selectively inhibits Mucorales growth.
- Albumin-deficient mice show increased susceptibility to mucormycosis.
- Albumin-bound free fatty acids (FFAs) are crucial for antifungal activity.
- High levels of oxidized FFAs correlate with poor outcomes in mucormycosis patients.
- Albumin prevents FFA oxidation, maintaining their antifungal properties.
- Albumin modulates the expression of virulence factors in Mucorales.
- Restoring albumin levels improves resistance to mucormycosis in animal models.
Takeaway
Albumin helps our body fight off a dangerous fungus called Mucorales by stopping it from growing and causing harm.
Methodology
The study involved analyzing serum albumin levels and their antifungal activity against Mucorales in various patient cohorts.
Potential Biases
Potential biases may arise from the retrospective nature of patient data collection.
Limitations
The study primarily focused on specific patient populations, which may limit the generalizability of the findings.
Participant Demographics
Patients with hematological malignancies and metabolic disorders, including diabetes and COVID-19.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website